Percutaneous Coronary RevascularizatiOn VERsus Coronary-Artery Bypass Grafting for Multivessel Disease in Patients With Left Ventricular Dysfunction (PROVERB)

NARecruitingINTERVENTIONAL
Enrollment

1,040

Participants

Timeline

Start Date

March 16, 2023

Primary Completion Date

July 16, 2030

Study Completion Date

July 16, 2033

Conditions
Heart FailureRevascularization
Interventions
PROCEDURE

Percutaneous coronary intervention

The studied intervention will be percutaneous coronary angioplasty with drug eluting stent implantation. Percutaneous coronary intervention may be performed during one single procedure or during staged procedures. The decision will be left at the investigator choice. PCI will be performed using drug eluting stent exclusively. The techniques for bifurcation lesions and chronic total occlusion angioplasty will be left at the operator choice. The choice of the drug eluting stent used will be left at the operator's choice. Anti-platelet therapy will be given to all patients randomized to PCI. The choice of the anti-thrombotic regiment and its duration will be left at the investigator choice (after assessment of initial presentation, bleeding and ischemic risks) but will have to comply with the European Society of Cardiology guidelines.

PROCEDURE

Coronary artery bypass grafting

Coronary artery bypass grafting technique will be total arterial revascularization unless internal mammary grafts are unavailable or have inadequate flow. All patients will be treated with anti-thrombotic therapy according to the European Society of Cardiology guidelines

Trial Locations (1)

94000

RECRUITING

Assistance Publique Hôpitaux de Paris - CHU HENRI MONDOR, Créteil

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER